Merck & Co., Inc. (MRK) EV/EBIT Ratio: 18.11x
Is Merck & Co., Inc.’s EV/EBIT ratio high or low?
Merck & Co., Inc.'s EV/EBIT ratio of 18.11x is 35% below its 5-year average of 27.81x, near the low end of its 5-year range (9.41x–124.09x).
As of Tuesday, June 16, 2026. 57.50% above its 12-month average of 11.50x.
MRK EV/EBIT Ratio Chart
MRK Average EV/EBIT Ratio Chart
MRK Current vs Average EV/EBIT Ratio Chart
MRK EV/EBIT Ratio Metrics
EV/EBIT RATIO
18.11x
EV/EBIT RATIO AVG TTM
11.50x
EV/EBIT RATIO AVG 3Y
25.17x
EV/EBIT RATIO AVG 5Y
23.26x
EV/EBIT RATIO AVG 10Y
23.15x
EV/EBIT RATIO AVG 15Y
21.11x
EV/EBIT RATIO AVG 20Y
21.33x
CURRENT VS TTM AVG
+57.50%
CURRENT VS 3Y AVG
-28.04%
CURRENT VS 5Y AVG
-22.14%
CURRENT VS 10Y AVG
-21.78%
CURRENT VS 15Y AVG
-14.22%
CURRENT VS 20Y AVG
-15.09%
MRK Competitors' EV/EBIT Ratio
| NAME | MARKET CAP | EV/EBIT RATIO | TTM | 3Y | 5Y |
|---|---|---|---|---|---|
| Merck & Co., Inc. (MRK) | $284.20B | 18.11x | 11.50x | 25.17x | 23.26x |
| AstraZeneca PLC (AZN)vs › | $277.15B | 21.33x | 23.87x | 26.82x | 345.81x |
| UnitedHealth Group Incorporated (UNH)vs › | $373.30B | 22.51x | 13.93x | 15.45x | 17.16x |
| Novo Nordisk A/S (NVO)vs › | $193.53B | 9.20x | 11.87x | 24.26x | 25.47x |
| Amgen Inc. (AMGN)vs › | $189.27B | 20.04x | 24.69x | 26.24x | 23.37x |
| Thermo Fisher Scientific Inc. (TMO)vs › | $177.08B | 26.99x | 28.32x | 30.54x | 28.33x |
| AbbVie Inc. (ABBV)vs › | $391.86B | 26.33x | 39.19x | 31.85x | 26.56x |
| Gilead Sciences, Inc. (GILD)vs › | $157.69B | 14.98x | 18.25x | 42.71x | 31.50x |
| Abbott Laboratories (ABT)vs › | $156.41B | 22.21x | 27.82x | 30.31x | 27.84x |
| Pfizer Inc. (PFE)vs › | $148.76B | 14.26x | 12.26x | 29.89x | 23.36x |
Merck & Co., Inc. EV/EBIT Ratio Formula & Definition
EV/EBIT = Enterprise Value / EBIT (TTM)
Enterprise value to EBIT compares total company value to operating earnings, accounting for depreciation unlike EV/EBITDA.
Expanded definitions: Investopedia, Wikipedia, Corporate Finance Institute
Merck & Co., Inc. EV/EBIT Ratio FAQ
- What is the EV/EBIT ratio for Merck & Co., Inc. (MRK)?
- The EV/EBIT ratio for MRK stock is 18.11x.
- Is Merck & Co., Inc.'s EV/EBIT ratio high or low?
- Merck & Co., Inc.'s EV/EBIT ratio of 18.11x is 35% below its 5-year average of 27.81x, near the low end of its 5-year range (9.41x–124.09x).
- What is the TTM average EV/EBIT ratio for Merck & Co., Inc. (MRK)?
- The TTM average EV/EBIT ratio for MRK stock is 11.50x.
- What is the 3Y average EV/EBIT ratio for Merck & Co., Inc. (MRK)?
- The 3Y average EV/EBIT ratio for MRK stock is 25.17x.
- What is the 5Y average EV/EBIT ratio for Merck & Co., Inc. (MRK)?
- The 5Y average EV/EBIT ratio for MRK stock is 23.26x.
- What is the 10Y average EV/EBIT ratio for Merck & Co., Inc. (MRK)?
- The 10Y average EV/EBIT ratio for MRK stock is 23.15x.
- What is the 15Y average EV/EBIT ratio for Merck & Co., Inc. (MRK)?
- The 15Y average EV/EBIT ratio for MRK stock is 21.11x.
- What is the 20Y average EV/EBIT ratio for Merck & Co., Inc. (MRK)?
- The 20Y average EV/EBIT ratio for MRK stock is 21.33x.
Merck & Co., Inc. EV/EBIT Ratio History
| DATE | EV/EBIT RATIO |
|---|---|
| 2026-06-15 | 18.11x |
| 2026-06-12 | 18.68x |
| 2026-06-11 | 18.91x |
| 2026-06-10 | 18.69x |
| 2026-06-09 | 18.76x |
| 2026-06-08 | 18.74x |
| 2026-06-05 | 18.92x |
| 2026-06-04 | 18.85x |
| 2026-06-03 | 18.09x |
| 2026-06-02 | 18.22x |
| 2026-06-01 | 18.15x |
| 2026-05-29 | 18.64x |
| 2026-05-28 | 18.80x |
| 2026-05-27 | 18.84x |
| 2026-05-26 | 18.77x |
| 2026-05-22 | 19.14x |
| 2026-05-21 | 18.25x |
| 2026-05-20 | 17.85x |
| 2026-05-19 | 18.02x |
| 2026-05-18 | 17.79x |
| 2026-05-15 | 17.63x |
| 2026-05-14 | 17.91x |
| 2026-05-13 | 17.92x |
| 2026-05-12 | 17.77x |
| 2026-05-11 | 17.62x |
| 2026-05-08 | 17.63x |
| 2026-05-07 | 17.76x |
| 2026-05-06 | 17.93x |
| 2026-05-05 | 17.87x |
| 2026-05-04 | 17.87x |
| 2026-05-01 | 11.80x |
| 2026-04-30 | 11.52x |
| 2026-04-29 | 11.69x |
| 2026-04-28 | 11.60x |
| 2026-04-27 | 11.62x |
| 2026-04-24 | 11.78x |
| 2026-04-23 | 12.03x |
| 2026-04-22 | 11.87x |
| 2026-04-21 | 11.84x |
| 2026-04-20 | 12.26x |
| 2026-04-17 | 12.45x |
| 2026-04-16 | 12.11x |
| 2026-04-15 | 12.34x |
| 2026-04-14 | 12.53x |
| 2026-04-13 | 12.55x |
| 2026-04-10 | 12.67x |
| 2026-04-09 | 12.78x |
| 2026-04-08 | 12.83x |
| 2026-04-07 | 12.47x |
| 2026-04-06 | 12.61x |
| 2026-04-02 | 12.61x |
| 2026-04-01 | 12.61x |
| 2026-03-31 | 12.56x |
| 2026-03-30 | 12.36x |
| 2026-03-27 | 12.50x |
| 2026-03-26 | 12.43x |
| 2026-03-25 | 12.47x |
| 2026-03-24 | 12.19x |
| 2026-03-23 | 12.13x |
| 2026-03-20 | 11.99x |
| 2026-03-19 | 11.99x |
| 2026-03-18 | 12.02x |
| 2026-03-17 | 12.15x |
| 2026-03-16 | 12.11x |
| 2026-03-13 | 12.12x |
| 2026-03-12 | 12.15x |
| 2026-03-11 | 12.18x |
| 2026-03-10 | 12.26x |
| 2026-03-09 | 12.26x |
| 2026-03-06 | 12.14x |
| 2026-03-05 | 12.17x |
| 2026-03-04 | 12.56x |
| 2026-03-03 | 12.52x |
| 2026-03-02 | 12.66x |
| 2026-02-27 | 12.89x |
| 2026-02-26 | 12.47x |
| 2026-02-25 | 12.76x |
| 2026-02-24 | 12.90x |
| 2026-02-23 | 13.36x |
| 2026-02-20 | 13.21x |
| 2026-02-19 | 13.17x |
| 2026-02-18 | 13.15x |
| 2026-02-17 | 13.14x |
| 2026-02-13 | 13.12x |
| 2026-02-12 | 12.90x |
| 2026-02-11 | 12.91x |
| 2026-02-10 | 12.69x |
| 2026-02-09 | 12.74x |
| 2026-02-06 | 13.17x |
| 2026-02-05 | 12.96x |
| 2026-02-04 | 12.81x |
| 2026-02-03 | 12.56x |
| 2026-02-02 | 12.32x |
| 2026-01-30 | 12.00x |
| 2026-01-29 | 11.81x |
| 2026-01-28 | 11.67x |
| 2026-01-27 | 11.77x |
| 2026-01-26 | 11.72x |
| 2026-01-23 | 11.79x |
| 2026-01-22 | 11.89x |
| 2026-01-21 | 12.09x |
| 2026-01-20 | 11.92x |
| 2026-01-16 | 11.86x |
| 2026-01-15 | 12.07x |
| 2026-01-14 | 12.08x |
| 2026-01-13 | 11.80x |
| 2026-01-12 | 11.90x |
| 2026-01-09 | 12.03x |
| 2026-01-08 | 12.08x |
| 2026-01-07 | 11.84x |
| 2026-01-06 | 11.86x |
| 2026-01-05 | 11.72x |
| 2026-01-02 | 11.62x |
| 2025-12-31 | 11.50x |
| 2025-12-30 | 11.58x |
| 2025-12-29 | 11.64x |
| 2025-12-26 | 11.65x |
| 2025-12-24 | 11.62x |
| 2025-12-23 | 11.48x |
| 2025-12-22 | 11.45x |
| 2025-12-19 | 11.08x |
| 2025-12-18 | 11.04x |
| 2025-12-17 | 10.89x |
| 2025-12-16 | 10.80x |
| 2025-12-15 | 11.00x |
| 2025-12-12 | 11.00x |
| 2025-12-11 | 10.87x |
| 2025-12-10 | 10.73x |
| 2025-12-09 | 10.66x |
| 2025-12-08 | 10.87x |
| 2025-12-05 | 10.94x |
| 2025-12-04 | 11.06x |
| 2025-12-03 | 11.20x |
| 2025-12-02 | 11.08x |
| 2025-12-01 | 11.16x |
| 2025-11-28 | 11.46x |
| 2025-11-26 | 11.44x |
| 2025-11-25 | 11.54x |
| 2025-11-24 | 11.01x |
| 2025-11-21 | 10.75x |
| 2025-11-20 | 10.47x |
| 2025-11-19 | 10.48x |
| 2025-11-18 | 10.61x |
| 2025-11-17 | 10.26x |
| 2025-11-14 | 10.26x |
| 2025-11-13 | 10.26x |
| 2025-11-12 | 10.11x |
| 2025-11-11 | 10.06x |
| 2025-11-10 | 9.64x |
| 2025-11-07 | 9.60x |
| 2025-11-06 | 9.55x |
| 2025-11-05 | 9.41x |
| 2025-11-04 | 11.13x |
| 2025-11-03 | 10.97x |
| 2025-10-31 | 11.38x |
| 2025-10-30 | 11.41x |
| 2025-10-29 | 11.45x |
| 2025-10-28 | 11.50x |
| 2025-10-27 | 11.61x |
| 2025-10-24 | 11.55x |
| 2025-10-23 | 11.52x |
| 2025-10-22 | 11.57x |
| 2025-10-21 | 11.57x |
| 2025-10-20 | 11.42x |
| 2025-10-17 | 11.24x |
| 2025-10-16 | 11.13x |
| 2025-10-15 | 11.16x |
| 2025-10-14 | 11.23x |
| 2025-10-13 | 11.34x |
| 2025-10-10 | 11.38x |
| 2025-10-09 | 11.55x |
| 2025-10-08 | 11.43x |
| 2025-10-07 | 11.57x |
| 2025-10-06 | 11.71x |
| 2025-10-03 | 11.75x |
| 2025-10-02 | 11.79x |
| 2025-10-01 | 11.86x |
| 2025-09-30 | 11.14x |
| 2025-09-29 | 10.51x |
| 2025-09-26 | 10.50x |
| 2025-09-25 | 10.39x |
| 2025-09-24 | 10.64x |
| 2025-09-23 | 10.67x |
| 2025-09-22 | 10.72x |
| 2025-09-19 | 10.85x |
| 2025-09-18 | 10.85x |
| 2025-09-17 | 10.81x |
| 2025-09-16 | 10.80x |
| 2025-09-15 | 10.79x |
| 2025-09-12 | 11.00x |
| 2025-09-11 | 11.28x |
| 2025-09-10 | 11.15x |
| 2025-09-09 | 11.22x |
| 2025-09-08 | 11.15x |
| 2025-09-05 | 11.23x |
| 2025-09-04 | 11.15x |
| 2025-09-03 | 11.16x |
| 2025-09-02 | 11.32x |
| 2025-08-29 | 11.16x |
| 2025-08-28 | 11.05x |
| 2025-08-27 | 11.15x |
| 2025-08-26 | 11.26x |
| 2025-08-25 | 11.30x |
| 2025-08-22 | 11.54x |
| 2025-08-21 | 11.39x |
| 2025-08-20 | 11.22x |
| 2025-08-19 | 11.25x |
| 2025-08-18 | 11.17x |
| 2025-08-15 | 11.17x |
| 2025-08-14 | 11.00x |
| 2025-08-13 | 10.99x |
| 2025-08-12 | 10.71x |
| 2025-08-11 | 10.68x |
| 2025-08-08 | 10.76x |
| 2025-08-07 | 10.72x |
| 2025-08-06 | 10.61x |
| 2025-08-05 | 10.77x |
| 2025-08-04 | 10.79x |
| 2025-08-01 | 10.72x |
| 2025-07-31 | 10.58x |
| 2025-07-30 | 11.01x |
| 2025-07-29 | 11.12x |
| 2025-07-28 | 11.29x |
| 2025-07-25 | 11.37x |
| 2025-07-24 | 11.29x |
| 2025-07-23 | 11.28x |
| 2025-07-22 | 11.00x |
| 2025-07-21 | 10.72x |
| 2025-07-18 | 10.80x |
| 2025-07-17 | 10.98x |
| 2025-07-16 | 11.09x |
| 2025-07-15 | 10.98x |
| 2025-07-14 | 11.24x |
| 2025-07-11 | 11.20x |
| 2025-07-10 | 11.28x |
| 2025-07-09 | 11.25x |
| 2025-07-08 | 10.97x |
| 2025-07-07 | 10.91x |
| 2025-07-03 | 10.91x |
| 2025-07-02 | 11.09x |
| 2025-07-01 | 11.02x |
| 2025-06-30 | 10.70x |
| 2025-06-27 | 10.70x |
| 2025-06-26 | 10.66x |
| 2025-06-25 | 10.76x |
| 2025-06-24 | 10.84x |
| 2025-06-23 | 10.82x |
| 2025-06-20 | 10.69x |
| 2025-06-18 | 10.72x |
| 2025-06-17 | 10.60x |
| 2025-06-16 | 10.92x |
| 2025-06-13 | 11.01x |
| 2025-06-12 | 11.02x |
| 2025-06-11 | 10.84x |
| 2025-06-10 | 10.96x |
| 2025-06-09 | 10.72x |
| 2025-06-06 | 10.68x |
| 2025-06-05 | 10.52x |
| 2025-06-04 | 10.60x |
| 2025-06-03 | 10.46x |
Showing the most recent 260 of 5,031 data points. The chart above shows the full history.
Related Metrics
About Merck & Co., Inc.
Merck & Co., Inc. is a global healthcare leader with operations spanning two core divisions: Pharmaceuticals and Animal Health. The Pharmaceutical segment is dedicated to human health, offering a broad spectrum of medicinal products. These cover crucial therapeutic areas such as oncology, acute hospital care, immunology, neuroscience, virology, cardiovascular conditions, and diabetes. This division also develops vital preventive vaccines for pediatric, adolescent, and adult populations. Meanwhile, the Animal Health segment focuses on the research, development, manufacturing, and marketing of veterinary medications, vaccines, and comprehensive health management solutions for animals. This division further provides innovative digital products designed for animal identification, traceability, and continuous monitoring. Merck's extensive clientele encompasses drug wholesalers, pharmacies, hospitals, and government agencies. It also serves managed healthcare organizations, including health maintenance organizations (HMOs) and pharmacy benefit managers, as well as various other institutional clients. Additionally, the company supplies products to individual physicians and their distributors, veterinarians, and livestock producers. The organization actively engages in strategic collaborations with companies such as AstraZeneca PLC, Bayer AG, Eisai Co., Ltd., Ridgeback Biotherapeutics, and Gilead Sciences, Inc. These partnerships are specifically aimed at the joint development and commercialization of prolonged-acting therapies for HIV. Established in 1891, Merck & Co., Inc. maintains its corporate headquarters in Kenilworth, New Jersey.
- Sector
- Healthcare
- Industry
- Drug Manufacturers - General
- CEO
- Robert Davis